|
||||||
|
 | Fusion Gene Summary |
| Fusion Gene ORF analysis |
| Fusion Genomic Features |
| Fusion Protein Features |
| Fusion Gene Sequence |
| Fusion Gene PPI analysis |
| Related Drugs |
| Related Diseases |
Fusion gene:SMG1-CYP2C9 (FusionGDB2 ID:83479) |
Fusion Gene Summary for SMG1-CYP2C9 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: SMG1-CYP2C9 | Fusion gene ID: 83479 | Hgene | Tgene | Gene symbol | SMG1 | CYP2C9 | Gene ID | 23049 | 1559 |
| Gene name | SMG1 nonsense mediated mRNA decay associated PI3K related kinase | cytochrome P450 family 2 subfamily C member 9 | |
| Synonyms | 61E3.4|ATX|LIP | CPC9|CYP2C|CYP2C10|CYPIIC9|P450IIC9 | |
| Cytomap | 16p12.3 | 10q23.33 | |
| Type of gene | protein-coding | protein-coding | |
| Description | serine/threonine-protein kinase SMG1PI-3-kinase-related kinase SMG-1SMG1 phosphatidylinositol 3-kinase-related kinaselambda-interacting proteinlambda/iota protein kinase C-interacting proteinsmg-1 homolog, phosphatidylinositol 3-kinase-related kinase | cytochrome P450 2C9cytochrome P-450 S-mephenytoin 4-hydroxylasecytochrome P-450MPcytochrome P450 PB-1cytochrome P450, family 2, subfamily C, polypeptide 9flavoprotein-linked monooxygenasemicrosomal monooxygenasexenobiotic monooxygenase | |
| Modification date | 20200313 | 20200313 | |
| UniProtAcc | . | P11712 | |
| Ensembl transtripts involved in fusion gene | ENST00000389467, ENST00000446231, ENST00000565224, ENST00000567737, | ENST00000260682, ENST00000461906, | |
| Fusion gene scores | * DoF score | 28 X 23 X 9=5796 | 4 X 3 X 3=36 |
| # samples | 31 | 4 | |
| ** MAII score | log2(31/5796*10)=-4.22471747428269 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(4/36*10)=0.15200309344505 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | |
| Context | PubMed: SMG1 [Title/Abstract] AND CYP2C9 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint | SMG1(18856751)-CYP2C9(96740952), # samples:1 | ||
| Anticipated loss of major functional domain due to fusion event. | SMG1-CYP2C9 seems lost the major protein functional domain in Hgene partner, which is a kinase due to the frame-shifted ORF. SMG1-CYP2C9 seems lost the major protein functional domain in Hgene partner, which is a cell metabolism gene due to the frame-shifted ORF. SMG1-CYP2C9 seems lost the major protein functional domain in Hgene partner, which is a IUPHAR drug target due to the frame-shifted ORF. SMG1-CYP2C9 seems lost the major protein functional domain in Tgene partner, which is a IUPHAR drug target due to the frame-shifted ORF. | ||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | SMG1 | GO:0000184 | nuclear-transcribed mRNA catabolic process, nonsense-mediated decay | 11544179 |
| Hgene | SMG1 | GO:0018105 | peptidyl-serine phosphorylation | 11544179|15175154 |
| Hgene | SMG1 | GO:0046777 | protein autophosphorylation | 11331269|11544179 |
| Hgene | SMG1 | GO:0046854 | phosphatidylinositol phosphorylation | 11331269 |
| Hgene | SMG1 | GO:2001020 | regulation of response to DNA damage stimulus | 15175154 |
| Tgene | CYP2C9 | GO:0008210 | estrogen metabolic process | 12865317 |
| Tgene | CYP2C9 | GO:0016098 | monoterpenoid metabolic process | 16401082 |
| Tgene | CYP2C9 | GO:0017144 | drug metabolic process | 19219744|19651758 |
| Tgene | CYP2C9 | GO:0019373 | epoxygenase P450 pathway | 7574697 |
| Tgene | CYP2C9 | GO:0019627 | urea metabolic process | 19029318 |
| Tgene | CYP2C9 | GO:0032787 | monocarboxylic acid metabolic process | 19651758 |
| Tgene | CYP2C9 | GO:0042738 | exogenous drug catabolic process | 18619574 |
| Tgene | CYP2C9 | GO:0043603 | cellular amide metabolic process | 19651758 |
| Tgene | CYP2C9 | GO:0046456 | icosanoid biosynthetic process | 15766564 |
| Tgene | CYP2C9 | GO:0055114 | oxidation-reduction process | 16401082|19219744 |
| Tgene | CYP2C9 | GO:0070989 | oxidative demethylation | 18619574 |
| Fusion gene breakpoints across SMG1 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene breakpoints across CYP2C9 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChiTaRS5.0 | N/A | AV652799 | SMG1 | chr16 | 18856751 | - | CYP2C9 | chr10 | 96740952 | + |
Top |
Fusion Gene ORF analysis for SMG1-CYP2C9 |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| Frame-shift | ENST00000389467 | ENST00000260682 | SMG1 | chr16 | 18856751 | - | CYP2C9 | chr10 | 96740952 | + |
| 5CDS-intron | ENST00000389467 | ENST00000461906 | SMG1 | chr16 | 18856751 | - | CYP2C9 | chr10 | 96740952 | + |
| Frame-shift | ENST00000446231 | ENST00000260682 | SMG1 | chr16 | 18856751 | - | CYP2C9 | chr10 | 96740952 | + |
| 5CDS-intron | ENST00000446231 | ENST00000461906 | SMG1 | chr16 | 18856751 | - | CYP2C9 | chr10 | 96740952 | + |
| intron-3CDS | ENST00000565224 | ENST00000260682 | SMG1 | chr16 | 18856751 | - | CYP2C9 | chr10 | 96740952 | + |
| intron-intron | ENST00000565224 | ENST00000461906 | SMG1 | chr16 | 18856751 | - | CYP2C9 | chr10 | 96740952 | + |
| intron-3CDS | ENST00000567737 | ENST00000260682 | SMG1 | chr16 | 18856751 | - | CYP2C9 | chr10 | 96740952 | + |
| intron-intron | ENST00000567737 | ENST00000461906 | SMG1 | chr16 | 18856751 | - | CYP2C9 | chr10 | 96740952 | + |
| ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
Top |
Fusion Genomic Features for SMG1-CYP2C9 |
| FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
| Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
Top |
Fusion Protein Features for SMG1-CYP2C9 |
| Go to FGviewer for the breakpoints of :-: - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| . | CYP2C9 |
| FUNCTION: Might normally function as a transcriptional repressor. EWS-fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. They may also contribute to an aberrant activation of the fusion protein target genes. | FUNCTION: A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids and steroids (PubMed:7574697, PubMed:9866708, PubMed:9435160, PubMed:12865317, PubMed:15766564, PubMed:19965576, PubMed:21576599). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase) (PubMed:7574697, PubMed:9866708, PubMed:9435160, PubMed:12865317, PubMed:15766564, PubMed:19965576, PubMed:21576599). Catalyzes the epoxidation of double bonds of polyunsaturated fatty acids (PUFA) (PubMed:7574697, PubMed:15766564, PubMed:19965576, PubMed:9866708). Catalyzes the hydroxylation of carbon-hydrogen bonds. Metabolizes cholesterol toward 25-hydroxycholesterol, a physiological regulator of cellular cholesterol homeostasis (PubMed:21576599). Exhibits low catalytic activity for the formation of catechol estrogens from 17beta-estradiol (E2) and estrone (E1), namely 2-hydroxy E1 and E2 (PubMed:12865317). Catalyzes bisallylic hydroxylation and hydroxylation with double-bond migration of polyunsaturated fatty acids (PUFA) (PubMed:9866708, PubMed:9435160). Also metabolizes plant monoterpenes such as limonene. Oxygenates (R)- and (S)-limonene to produce carveol and perillyl alcohol (PubMed:11950794). Contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenytoin, tolbutamide and losartan (PubMed:25994031). {ECO:0000269|PubMed:11950794, ECO:0000269|PubMed:12865317, ECO:0000269|PubMed:15766564, ECO:0000269|PubMed:19965576, ECO:0000269|PubMed:21576599, ECO:0000269|PubMed:25994031, ECO:0000269|PubMed:7574697, ECO:0000269|PubMed:9435160, ECO:0000269|PubMed:9866708}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
Fusion Gene Sequence for SMG1-CYP2C9 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
Top |
Fusion Gene PPI Analysis for SMG1-CYP2C9 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for SMG1-CYP2C9 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Tgene | CYP2C9 | P11712 | DB11994 | Diacerein | Inhibitor | Small molecule | Approved|Investigational |
| Tgene | CYP2C9 | P11712 | DB11994 | Diacerein | Inhibitor | Small molecule | Approved|Investigational |
Top |
Related Diseases for SMG1-CYP2C9 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Tgene | CYP2C9 | C0019080 | Hemorrhage | 5 | CTD_human |
| Tgene | CYP2C9 | C0041696 | Unipolar Depression | 4 | PSYGENET |
| Tgene | CYP2C9 | C1269683 | Major Depressive Disorder | 4 | PSYGENET |
| Tgene | CYP2C9 | C0013221 | Drug toxicity | 3 | CTD_human |
| Tgene | CYP2C9 | C0019193 | Hepatitis, Toxic | 3 | CTD_human |
| Tgene | CYP2C9 | C0041755 | Adverse reaction to drug | 3 | CTD_human |
| Tgene | CYP2C9 | C0860207 | Drug-Induced Liver Disease | 3 | CTD_human |
| Tgene | CYP2C9 | C1262760 | Hepatitis, Drug-Induced | 3 | CTD_human |
| Tgene | CYP2C9 | C3658290 | Drug-Induced Acute Liver Injury | 3 | CTD_human |
| Tgene | CYP2C9 | C4277682 | Chemical and Drug Induced Liver Injury | 3 | CTD_human |
| Tgene | CYP2C9 | C4279912 | Chemically-Induced Liver Toxicity | 3 | CTD_human |
| Tgene | CYP2C9 | C0006118 | Brain Neoplasms | 1 | CTD_human |
| Tgene | CYP2C9 | C0013182 | Drug Allergy | 1 | CTD_human |
| Tgene | CYP2C9 | C0022660 | Kidney Failure, Acute | 1 | CTD_human |
| Tgene | CYP2C9 | C0027707 | Nephritis, Interstitial | 1 | CTD_human |
| Tgene | CYP2C9 | C0027765 | nervous system disorder | 1 | CTD_human |
| Tgene | CYP2C9 | C0030922 | Peptic Ulcer Hemorrhage | 1 | CTD_human |
| Tgene | CYP2C9 | C0033141 | Cardiomyopathies, Primary | 1 | CTD_human |
| Tgene | CYP2C9 | C0036529 | Myocardial Diseases, Secondary | 1 | CTD_human |
| Tgene | CYP2C9 | C0041349 | Nephritis, Tubulointerstitial | 1 | CTD_human |
| Tgene | CYP2C9 | C0153633 | Malignant neoplasm of brain | 1 | CTD_human |
| Tgene | CYP2C9 | C0496899 | Benign neoplasm of brain, unspecified | 1 | CTD_human |
| Tgene | CYP2C9 | C0750974 | Brain Tumor, Primary | 1 | CTD_human |
| Tgene | CYP2C9 | C0750977 | Recurrent Brain Neoplasm | 1 | CTD_human |
| Tgene | CYP2C9 | C0750979 | Primary malignant neoplasm of brain | 1 | CTD_human |
| Tgene | CYP2C9 | C0878544 | Cardiomyopathies | 1 | CTD_human |
| Tgene | CYP2C9 | C1527390 | Neoplasms, Intracranial | 1 | CTD_human |
| Tgene | CYP2C9 | C1565662 | Acute Kidney Insufficiency | 1 | CTD_human |
| Tgene | CYP2C9 | C2608079 | WARFARIN SENSITIVITY (disorder) | 1 | CTD_human |
| Tgene | CYP2C9 | C2609414 | Acute kidney injury | 1 | CTD_human |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies